A China Ebola vaccine developed by Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology completed a successful Phase I trial in Jiangsu, with results published in The Lancet. The vaccine is the first candidate tested that was developed to fight the current 2014 Zaire Guinea Ebola strain of the virus. The candidate was safe and provoked an immune response, though it still needs to prove that it can protect against the virus. The vaccine is delivered by a virus-like structure.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
